- A Form-483 was issued by the US Food and Drug Administration (USFDA) after detecting procedural errors at Lupin’s Nagpur injectable manufacturing facility.
- Between October 17 and October 29, the USFDA conducted an examination of the plant and discovered five violations, including flaws in the flooring, walls, and ceiling of the aseptic processing sections.
- Lupin declared, “We’re dedicated to responding to the observations as soon as possible.
